2025 Q3 -tulosraportti
95 päivää sitten
‧27 min
Tarjoustasot
First North Sweden
Määrä
Osto
146
Myynti
Määrä
156
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 806 | - | - | ||
| 542 | - | - | ||
| 400 | - | - | ||
| 21 | - | - | ||
| 10 | - | - |
Ylin
15,88VWAP
Alin
15,2VaihtoMäärä
0 1 779
VWAP
Ylin
15,88Alin
15,2VaihtoMäärä
0 1 779
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 779 | 1 779 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 779 | 1 779 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 19.2. | 3 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 6.2.2025 | ||
2024 Q3 -tulosraportti 14.11.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·3.2.This company is currently priced at 35 million DKK! That's completely ridiculous, the price should be x10 in my opinion. This is not a recommendation to buy/sell. I have many, as in very many.
·3.2.ExpreS2ion Biotech reports encouraging immunogenicity observations from ongoing Phase I trial with ES2B-C001 Hørsholm, Denmark, February 3, 2026 – ExpreS2ion Biotech Holding AB's subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a clinical-stage biotechnology company with a focused pipeline of vaccine candidates targeting infectious diseases and cancer, today reports updated immunogenicity observations from its ongoing Phase I clinical trial with ES2B-C001, a HER2-targeted cancer vaccine candidate. Based on currently available data, five out of six evaluable patients have shown a drug-specific immune response, defined as an increase from baseline in anti-HER2 lambda light chain antibody titers after treatment with ES2B-C001. The data are still early and under evaluation, and no formal conclusions can be drawn at this time. The updated assessment includes immunogenicity data available up to the end of January 2026 from patients treated in the first dose cohort (50 micrograms plus adjuvant) as well as initial observations from patients included in the subsequent higher dose cohort (150 micrograms plus adjuvant). The data are still early and limited in scope, and further patient follow-up and data are necessary before final conclusions can be drawn. Based on the data currently available, five out of six evaluable patients have shown a drug-specific immune response, defined as an increase from baseline in anti-HER2 lambda light chain antibody titers after treatment with ES2B-C001. These lambda light chain antibody responses are specific to the vaccine-induced immune response. To date, two patients have completed all planned study visits and continue to show sustained elevated anti-HER2 lambda light chain Ig titers over time, suggesting durability of the observed immune response. Additional patients remain in treatment, and follow-up is ongoing. Commenting on the update Bent U. Frandsen, CEO of ExpreS2ion, commented: "Although the dataset remains limited and early, we are encouraged by the consistency observed in the immune responses in patients treated with ES2B-C001. More importantly, we continue to see vaccine-specific antibody responses without new safety concerns, which supports the continued progression of the clinical program." Dr. Erik Heegard, Director of Clinical Development, commented: "From a clinical and immunological perspective, the timing and pattern of the observed responses are consistent with what we would expect from an active cancer vaccine. At the same time, the small number of patients and the heterogeneity of previous and concomitant treatments mean that careful follow-up and additional data are needed before conclusions can be drawn." ExpreS2ion emphasizes that the current dataset remains limited and that the reported observations should be interpreted with caution. The company continues to work closely with investigators and the Data Safety Monitoring Board as the study progresses and further data matures. Patient enrollment and screening continue as planned, and clinics report that additional patients are available to proceed once dosing is permitted after the necessary safety reviews. Based on current visibility, ExpreS2ion remains on track to complete the dose-escalation part of the study around mid-2026 and the expansion part towards the end of 2026, depending on ongoing recruitment, safety reviews, and overall study conduct. Further updates will be provided as needed. About the ES2B-C001 Phase I trial The ES2B-C001 Phase I trial is an open-label study evaluating the safety, tolerability, and immunogenicity of ES2B-C001 in patients with advanced HER2-positive or HER2-low breast cancer who have previously received standard treatment. The study is being conducted at several clinical centers in Austria and includes a dose-escalation phase followed by an expansion phase. ES2B-C001 is administered as an intramuscular vaccine with adjuvant across multiple dose levels. The study's primary objective is to assess safety and tolerability with immunogenicity as a secondary objective. About ES2B-C001 (HER2-VLP) ES2B-C001 is an innovative immunotherapy developed for the treatment of HER2-expressing cancers by stimulating the patient's own immune system and offers a new alternative to existing antibody-based approaches. This approach combines ExpreS2ion's ExpreS2 production platform with AdaptVac's VLP technology, both of which have been proven in clinical Phase III. The HER2-VLP vaccine is designed to stimulate a robust and durable polyclonal immune response against HER2-expressing tumors and offers a complementary strategy to current treatment regimens such as monoclonal antibodies (mAb) or antibody-drug conjugate (ADC) therapies. Preclinical studies ( Ruzzi et al. (2022)
·3.2.Just remember now... how low the market capitalization is... That someone isn't putting a couple of hundred mill. here.- 3.2.3.2.
·3.2.Fair value at 28 sek·3.2.Fair value of a company without stable revenues, yes, it doesn't get any flimsier than that.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
95 päivää sitten
‧27 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3.2.This company is currently priced at 35 million DKK! That's completely ridiculous, the price should be x10 in my opinion. This is not a recommendation to buy/sell. I have many, as in very many.
- ·3.2.ExpreS2ion Biotech reports encouraging immunogenicity observations from ongoing Phase I trial with ES2B-C001 Hørsholm, Denmark, February 3, 2026 – ExpreS2ion Biotech Holding AB's subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a clinical-stage biotechnology company with a focused pipeline of vaccine candidates targeting infectious diseases and cancer, today reports updated immunogenicity observations from its ongoing Phase I clinical trial with ES2B-C001, a HER2-targeted cancer vaccine candidate. Based on currently available data, five out of six evaluable patients have shown a drug-specific immune response, defined as an increase from baseline in anti-HER2 lambda light chain antibody titers after treatment with ES2B-C001. The data are still early and under evaluation, and no formal conclusions can be drawn at this time. The updated assessment includes immunogenicity data available up to the end of January 2026 from patients treated in the first dose cohort (50 micrograms plus adjuvant) as well as initial observations from patients included in the subsequent higher dose cohort (150 micrograms plus adjuvant). The data are still early and limited in scope, and further patient follow-up and data are necessary before final conclusions can be drawn. Based on the data currently available, five out of six evaluable patients have shown a drug-specific immune response, defined as an increase from baseline in anti-HER2 lambda light chain antibody titers after treatment with ES2B-C001. These lambda light chain antibody responses are specific to the vaccine-induced immune response. To date, two patients have completed all planned study visits and continue to show sustained elevated anti-HER2 lambda light chain Ig titers over time, suggesting durability of the observed immune response. Additional patients remain in treatment, and follow-up is ongoing. Commenting on the update Bent U. Frandsen, CEO of ExpreS2ion, commented: "Although the dataset remains limited and early, we are encouraged by the consistency observed in the immune responses in patients treated with ES2B-C001. More importantly, we continue to see vaccine-specific antibody responses without new safety concerns, which supports the continued progression of the clinical program." Dr. Erik Heegard, Director of Clinical Development, commented: "From a clinical and immunological perspective, the timing and pattern of the observed responses are consistent with what we would expect from an active cancer vaccine. At the same time, the small number of patients and the heterogeneity of previous and concomitant treatments mean that careful follow-up and additional data are needed before conclusions can be drawn." ExpreS2ion emphasizes that the current dataset remains limited and that the reported observations should be interpreted with caution. The company continues to work closely with investigators and the Data Safety Monitoring Board as the study progresses and further data matures. Patient enrollment and screening continue as planned, and clinics report that additional patients are available to proceed once dosing is permitted after the necessary safety reviews. Based on current visibility, ExpreS2ion remains on track to complete the dose-escalation part of the study around mid-2026 and the expansion part towards the end of 2026, depending on ongoing recruitment, safety reviews, and overall study conduct. Further updates will be provided as needed. About the ES2B-C001 Phase I trial The ES2B-C001 Phase I trial is an open-label study evaluating the safety, tolerability, and immunogenicity of ES2B-C001 in patients with advanced HER2-positive or HER2-low breast cancer who have previously received standard treatment. The study is being conducted at several clinical centers in Austria and includes a dose-escalation phase followed by an expansion phase. ES2B-C001 is administered as an intramuscular vaccine with adjuvant across multiple dose levels. The study's primary objective is to assess safety and tolerability with immunogenicity as a secondary objective. About ES2B-C001 (HER2-VLP) ES2B-C001 is an innovative immunotherapy developed for the treatment of HER2-expressing cancers by stimulating the patient's own immune system and offers a new alternative to existing antibody-based approaches. This approach combines ExpreS2ion's ExpreS2 production platform with AdaptVac's VLP technology, both of which have been proven in clinical Phase III. The HER2-VLP vaccine is designed to stimulate a robust and durable polyclonal immune response against HER2-expressing tumors and offers a complementary strategy to current treatment regimens such as monoclonal antibodies (mAb) or antibody-drug conjugate (ADC) therapies. Preclinical studies ( Ruzzi et al. (2022)
- ·3.2.Just remember now... how low the market capitalization is... That someone isn't putting a couple of hundred mill. here.
- 3.2.3.2.·3.2.Fair value at 28 sek·3.2.Fair value of a company without stable revenues, yes, it doesn't get any flimsier than that.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
146
Myynti
Määrä
156
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 806 | - | - | ||
| 542 | - | - | ||
| 400 | - | - | ||
| 21 | - | - | ||
| 10 | - | - |
Ylin
15,88VWAP
Alin
15,2VaihtoMäärä
0 1 779
VWAP
Ylin
15,88Alin
15,2VaihtoMäärä
0 1 779
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 779 | 1 779 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 779 | 1 779 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 19.2. | 3 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 6.2.2025 | ||
2024 Q3 -tulosraportti 14.11.2024 |
2025 Q3 -tulosraportti
95 päivää sitten
‧27 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 19.2. | 3 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 6.2.2025 | ||
2024 Q3 -tulosraportti 14.11.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3.2.This company is currently priced at 35 million DKK! That's completely ridiculous, the price should be x10 in my opinion. This is not a recommendation to buy/sell. I have many, as in very many.
- ·3.2.ExpreS2ion Biotech reports encouraging immunogenicity observations from ongoing Phase I trial with ES2B-C001 Hørsholm, Denmark, February 3, 2026 – ExpreS2ion Biotech Holding AB's subsidiary ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a clinical-stage biotechnology company with a focused pipeline of vaccine candidates targeting infectious diseases and cancer, today reports updated immunogenicity observations from its ongoing Phase I clinical trial with ES2B-C001, a HER2-targeted cancer vaccine candidate. Based on currently available data, five out of six evaluable patients have shown a drug-specific immune response, defined as an increase from baseline in anti-HER2 lambda light chain antibody titers after treatment with ES2B-C001. The data are still early and under evaluation, and no formal conclusions can be drawn at this time. The updated assessment includes immunogenicity data available up to the end of January 2026 from patients treated in the first dose cohort (50 micrograms plus adjuvant) as well as initial observations from patients included in the subsequent higher dose cohort (150 micrograms plus adjuvant). The data are still early and limited in scope, and further patient follow-up and data are necessary before final conclusions can be drawn. Based on the data currently available, five out of six evaluable patients have shown a drug-specific immune response, defined as an increase from baseline in anti-HER2 lambda light chain antibody titers after treatment with ES2B-C001. These lambda light chain antibody responses are specific to the vaccine-induced immune response. To date, two patients have completed all planned study visits and continue to show sustained elevated anti-HER2 lambda light chain Ig titers over time, suggesting durability of the observed immune response. Additional patients remain in treatment, and follow-up is ongoing. Commenting on the update Bent U. Frandsen, CEO of ExpreS2ion, commented: "Although the dataset remains limited and early, we are encouraged by the consistency observed in the immune responses in patients treated with ES2B-C001. More importantly, we continue to see vaccine-specific antibody responses without new safety concerns, which supports the continued progression of the clinical program." Dr. Erik Heegard, Director of Clinical Development, commented: "From a clinical and immunological perspective, the timing and pattern of the observed responses are consistent with what we would expect from an active cancer vaccine. At the same time, the small number of patients and the heterogeneity of previous and concomitant treatments mean that careful follow-up and additional data are needed before conclusions can be drawn." ExpreS2ion emphasizes that the current dataset remains limited and that the reported observations should be interpreted with caution. The company continues to work closely with investigators and the Data Safety Monitoring Board as the study progresses and further data matures. Patient enrollment and screening continue as planned, and clinics report that additional patients are available to proceed once dosing is permitted after the necessary safety reviews. Based on current visibility, ExpreS2ion remains on track to complete the dose-escalation part of the study around mid-2026 and the expansion part towards the end of 2026, depending on ongoing recruitment, safety reviews, and overall study conduct. Further updates will be provided as needed. About the ES2B-C001 Phase I trial The ES2B-C001 Phase I trial is an open-label study evaluating the safety, tolerability, and immunogenicity of ES2B-C001 in patients with advanced HER2-positive or HER2-low breast cancer who have previously received standard treatment. The study is being conducted at several clinical centers in Austria and includes a dose-escalation phase followed by an expansion phase. ES2B-C001 is administered as an intramuscular vaccine with adjuvant across multiple dose levels. The study's primary objective is to assess safety and tolerability with immunogenicity as a secondary objective. About ES2B-C001 (HER2-VLP) ES2B-C001 is an innovative immunotherapy developed for the treatment of HER2-expressing cancers by stimulating the patient's own immune system and offers a new alternative to existing antibody-based approaches. This approach combines ExpreS2ion's ExpreS2 production platform with AdaptVac's VLP technology, both of which have been proven in clinical Phase III. The HER2-VLP vaccine is designed to stimulate a robust and durable polyclonal immune response against HER2-expressing tumors and offers a complementary strategy to current treatment regimens such as monoclonal antibodies (mAb) or antibody-drug conjugate (ADC) therapies. Preclinical studies ( Ruzzi et al. (2022)
- ·3.2.Just remember now... how low the market capitalization is... That someone isn't putting a couple of hundred mill. here.
- 3.2.3.2.·3.2.Fair value at 28 sek·3.2.Fair value of a company without stable revenues, yes, it doesn't get any flimsier than that.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
146
Myynti
Määrä
156
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 806 | - | - | ||
| 542 | - | - | ||
| 400 | - | - | ||
| 21 | - | - | ||
| 10 | - | - |
Ylin
15,88VWAP
Alin
15,2VaihtoMäärä
0 1 779
VWAP
Ylin
15,88Alin
15,2VaihtoMäärä
0 1 779
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 779 | 1 779 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 1 779 | 1 779 | 0 | 0 |